Perifosine (NSC-639966)

Catalog No. A10709

Perifosine (也为KRX-0401) 充当Akt抑制剂和PI3K抑制剂。

Product Citations

Bjune K, .et al. Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms, PLoS One, 2019, Jun 19;14(6):e0218537 PMID: 31216345
Kyoung-Jae Won, .et al. Stability of the cancer target DDIAS is regulated by the CHIP/HSP70 pathway in lung cancer cells, Cell Death Dis, 2017, Jan; 8(1): e2554 PMID: 28079882
Zhipeng Li, .et al. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-κB regulates head and neck squamous cell carcinoma proliferation, Oncotarget, 2016, May 31; 7(22): 31892–31906 PMID: 26895469
Won KJ, .et al. NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription., Apoptosis., 2014, Jan;19(1):179-90 PMID: 24085402

Technical details

Catalog Num	A10709
M. Wt	461.7
Formula	C25H52NO4P
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	157716-52-4
Synonyms	KRX-0401,NSC 639966
SMILES	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

Biological Activity

Perifosine (也为KRX-0401) 充当Akt抑制剂和PI3K抑制剂。

Targets

Akt (MM.1S cells)
4.7 μM

Solubility *

In vitro (25°C)	DMSO	Insoluble
	Water	85 mg/mL (184.11mM)
	Ethanol	85 mg/mL (184.11mM)
In vivo	water	7 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	21.66 mL	108.3 mL	216.59 mL
0.5 mM	4.33 mL	21.66 mL	43.32 mL
1 mM	2.17 mL	10.83 mL	21.66 mL
5 mM	0.43 mL	2.17 mL	4.33 mL

*The above data is based on the productmolecular weight 461.7 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.